A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to assess the safety and tolerability of lucerastat in
adults with Fabry Disease receiving Enzyme Replacement Therapy (ERT).
The secondary objectives were to investigate the effects of lucerastat on plasma and urine
levels of biomarkers, to assess its effects on renal and cardiac functions and to determine
the pharmacokinetic profile of lucerastat at steady-state.